Cita APA

Ameratunga, M., Braña Garcia, I., Bono, P., Postel-Vinay, S., Plummer, R., & Aspegren, J. (2020). First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.

Citación estilo Chicago

Ameratunga, Malaka, Irene Braña Garcia, Petri Bono, Sophie Postel-Vinay, Ruth Plummer, y John Aspegren. First-in-human Phase 1 Open Label Study of the BET Inhibitor ODM-207 in Patients With Selected Solid Tumours. 2020.

Cita MLA

Ameratunga, Malaka, et al. First-in-human Phase 1 Open Label Study of the BET Inhibitor ODM-207 in Patients With Selected Solid Tumours. 2020.